If enacted, lawmakers will hold the right to monitor and restrict American companies from signing certain deals with Chinese entities.
Michigan lawmakers are looking to enact a policy that would restrict American dealmaking with Chinese biotech and pharma companies. Credit: OnePixelStudio / Shutterstock.com.
Two bipartisan Michigan lawmakers have joined forces to debut new legislation that, if enacted, could significantly suppress dealmaking between Chinese and American biotech and pharma companies.
Together, Republican John Moolenaar and Democrat Debbie Dingell have proposed the Biotech Investment National Security Act (BINSA). Acting as an amendment to the Comprehensive Outbound Investment National Security (COINS) Act of December 2025, which set out in part to curb China’s burgeoning dominance in the tech field, BINSA would allow US lawmakers to monitor and impose severe restrictions on American investments into foreign technology sectors. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
